Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other Non-Current Liabilities (2016 - 2020)

Syndax Pharmaceuticals has reported Other Non-Current Liabilities over the past 6 years, most recently at $1000.0 for Q4 2020.

  • Quarterly results put Other Non-Current Liabilities at $1000.0 for Q4 2020, down 80.0% from a year ago — trailing twelve months through Dec 2020 was $1000.0 (down 80.0% YoY), and the annual figure for FY2020 was $1000.0, down 80.0%.
  • Other Non-Current Liabilities for Q4 2020 was $1000.0 at Syndax Pharmaceuticals, down from $2000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for SNDX hit a ceiling of $312000.0 in Q1 2018 and a floor of $1000.0 in Q4 2020.
  • Median Other Non-Current Liabilities over the past 5 years was $148000.0 (2017), compared with a mean of $143350.0.
  • Biggest five-year swings in Other Non-Current Liabilities: surged 110.81% in 2018 and later crashed 97.76% in 2019.
  • Syndax Pharmaceuticals' Other Non-Current Liabilities stood at $288000.0 in 2016, then grew by 7.64% to $310000.0 in 2017, then tumbled by 56.13% to $136000.0 in 2018, then tumbled by 96.32% to $5000.0 in 2019, then crashed by 80.0% to $1000.0 in 2020.
  • The last three reported values for Other Non-Current Liabilities were $1000.0 (Q4 2020), $2000.0 (Q3 2020), and $3000.0 (Q2 2020) per Business Quant data.